Journal Mobile Options
Table of Contents
Vol. 34, No. 1, 2005
Issue release date: November 2005
Section title: Original Paper
Pathophysiol Haemos Thromb 2005;34:6–12

Long-Term Prospective Study of Recurrent Venous Thromboembolism in Patients Younger than 50 Years

García-Fuster M.-J.a · Forner M.-J.a · Fernández C.a · Gil J.b · Vaya A.c · Maldonado L.b
aService of Internal Medicine and bService of Radiology, Hospital Clínico Universitario, cThrombosis and Haemostasis Unit, Hospital La Fe, Valencia, Spain
email Corresponding Author

María-José García-Fuster, MD

Service of Internal Medicine, Hospital Clínico Universitario

Avda. Blasco Ibáñez 10

ES–46010 Valencia (Spain)

Tel./Fax +34 96 3862647, E-Mail


  1. White RH: The epidemiology of venous thromboembolism. Circulation 2003;107:I-4–I-8.
    External Resources
  2. Kearon C: Natural history of venous thromboembolism. Circulation 2003;107:I-22–I-30.
  3. Lamping DL, Schroter S, Kurz X, et al: Evaluation of outcomes in chronic venous disorders of the leg: development of a scientifically rigorous, patient-reported measure of symptoms and quality of life. J Vasc Surg 2003;37:410–419.
  4. Kahn SR, Hirsch A, Shrier I: Effect of postthrombotic syndrome on health-related quality of life after deep venous thrombosis. Arch Intern Med 2002;27:1144–1148.
  5. Palareti G, Cosmi B: Predicting the risk of recurrence of venous thromboembolism. Curr Opin Hematol 2004;11:192–197.
  6. Schulman S, Rhedin AS, Lindmarker P, et al: A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 1995;332:1661–1665.
  7. Lindmarker P, Schulman S, Sten-Linder M, et al: The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation. Thromb Haemost 1999;81:684–689.
  8. Heit JA, Mohr DN, Silverstein MD, et al: Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000;160:761–768.
  9. Cushman M, Tsai A, Heckbert SR, et al: Incidence rates, case fatality, and recurrence rates of deep thrombosis and pulmonary embolus: the Longitudinal Investigation of Thromboembolism Etiology (LITE) (abstract). Thromb Haemost 2001;86(suppl 1): OC2349.
  10. Arcelus JI, Caprini JA, Monreal M, et al: The management and outcome of acute venous thromboembolism: a prospective registry including 4,011 patients. J Vasc Surg 2003;38:916–922.
  11. Prandoni P, Lensing AW, Cogo A, et al: The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1–7.
  12. Hansson PO, Sörbo J, Eriksson H: Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000;160:769–774.
  13. Patel RK, Ford E, Thumpston J, et al: Risk factors for venous thrombosis in the black population. Thromb Haemost 2003;90:835–838.
  14. Prandoni P, Cogo A, Bernardi E, et al: A simple ultrasound approach for detection of recurrent proximal-vein thrombosis. Thromb Haemost 1993;88:1730–1735.
  15. Levine JS, Branch DW, Rauch J: The antiphospholipid syndrome. N Engl J Med 2002;346:752–763.
  16. García-Fuster MJ, Fernández C, Forner MJ, et al: Risk factors and clinical characteristics at thromboembolic venous disease in young patients: a prospective study. Med Clin (Barc) 2004;123:217–219.
  17. Prandoni P, Cogo A, Bernardi E, et al: A simple ultrasound approach for detection of recurrent proximal-vein thrombosis. Thromb Haemost 1993;88:1730–1735.
  18. White RH, Beyth RJ, Zhou H, et al: Major bleeding after hospitalization for deep-venous thrombosis. Am J Med 1999;107:414–424.
  19. Levine MN, Raskob G, Landefeld S, et al: Hemorrhagic complications of anticoagulant treatment. Chest 2001;119:S108–S121.
    External Resources
  20. Pengo V, Lensing AWA, Prins MH, et al: Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004;350:2257–2264.
  21. Prandoni P, Lensing AW, Prins MH, et al: Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002;137:955–960.
  22. Khamashta MA, Cuadrado MJ, Mujic F, et al: The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995;332:993–997.
  23. Schulman S, Svenungsson E, Granqvist S: Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med 1998;104:332–338.
  24. Ridker PM, Miletich JP, Stampfer MJ, et al: Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995;92:2800–2802.
  25. Simioni P, Prandoni P, Lensing AW, et al: The risk of recurrent venous thromboembolism in patients with an Arg506→Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997;336:399–403.
  26. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al: A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933–938.
  27. Kniffin WD Jr, Baron JA, Barrett J, et al: The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 1994;154:861–866.
  28. Kyrle PA, Minar E, Bialonczyk C, et al: The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004;350:2558–2563.
  29. Abdollahi M, Cushman M, Rosendaal FR: Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003;89:493–498.
  30. Ridker PM, Goldhaber SZ, Danielson E, et al: Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1425–1434.
  31. Schulman S, Wahlander K, Lundstrom T, et al: Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349:1713–1721.